HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Appel, G. B. Articles by Brenner, B. M. Search for Related Content PubMed PubMed Citation Articles by Appel, G. B. Articles by Brenner, B. M. Social Bookmarking                What's this?

Analysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study

¹ Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York
² Division of Nephrology, Long Island College Hospital, Brooklyn, New York
³ Diabetes Division, University of Texas Health Science Center, San Antonio, Texas
⁴ Hospital Clinico San Cecilio Endocrine Service, Granada, Spain
⁵ Hypertension Research Clinic, University of Calgary, Calgary, Canada
⁶ Merck Research Laboratories, Blue Bell, Pennsylvania
⁷ Renal Division, Brigham and Women’s Hospital, Boston, Massachusetts

OBJECTIVE—Metabolic factors such as glycemic control, hyperlipidemia, and hyperkalemia are important considerations in the treatment of patients with type 2 diabetes and nephropathy. In the RENAAL (Reduction of End Points in Type 2 Diabetes With the Angiotensin II Antagonist Losartan) study, losartan reduced renal outcomes in the patient population. This post hoc analysis of the RENAAL study reports the effects of losartan on selected metabolic parameters and assesses the relationship between baseline values of metabolic parameters and the primary composite end point or end-stage renal disease (ESRD).

RESEARCH DESIGN AND METHODS—Glycemic control (HbA_1c) and serum lipid, uric acid, and potassium levels were compared between the losartan and placebo groups over time, and baseline levels were correlated with the risk of reaching the primary composite end point (doubling of serum creatinine, ESRD, or death) or ESRD alone.

RESULTS—Losartan did not adversely affect glycemic control or serum lipid levels. Losartan-treated patients had lower total (227.4 vs. 195.4 mg/dl) and LDL (142.2 vs. 111.7 mg/dl) cholesterol. Losartan was associated with a mean increase of up to 0.3 mEq/l in serum potassium levels; however, the rate of hyperkalemia-related discontinuation was similar between the placebo and losartan groups. Univariate analysis revealed that baseline total and LDL cholesterol and triglyceride levels were associated with increased risk of developing the primary composite end point. Similarly, total and LDL cholesterol were also associated with increased risk of developing ESRD.

CONCLUSIONS—Overall, losartan was well tolerated by patients with type 2 diabetes and nephropathy and was associated with a favorable effect on the metabolic profile of this population.

Abbreviations: AIIA, angiotensin II receptor antagonist • ESRD, end-stage renal disease • Lp(a), lipoprotein a • RAAS, renin-angiotensin-aldosterone system • RENAAL, Reduction of End Points in Type 2 Diabetes With the Angiotensin II Antagonist Losartan

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. M. Tershakovec, W. F. Keane, Z. Zhang, P. A. Lyle, G. B. Appel, J. B. McGill, H.-H. Parving, M. E. Cooper, S. Shahinfar, and B. M. Brenner Effect of LDL Cholesterol and Treatment With Losartan on End-Stage Renal Disease in the RENAAL Study Diabetes Care, March 1, 2008; 31(3): 445 - 447. [Abstract] [Full Text] [PDF]

				H.-M. Jin and Y. Pan Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1943 - 1949. [Abstract] [Full Text] [PDF]

				R. Trevisan, A. R. Dodesini, and G. Lepore Lipids and Renal Disease J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S145 - S147. [Abstract] [Full Text] [PDF]

				K. J. Evans and A. Greenberg Hyperkalemia: A Review J Intensive Care Med, September 1, 2005; 20(5): 272 - 290. [Abstract] [PDF]

				N. R. Burrows, A. S. Narva, L. S. Geiss, M. M. Engelgau, and K. J. Acton End-Stage Renal Disease due to Diabetes Among Southwestern American Indians, 1990-2001 Diabetes Care, May 1, 2005; 28(5): 1041 - 1044. [Abstract] [Full Text] [PDF]

				J. L. Gross, M. J. de Azevedo, S. P. Silveiro, L. H. Canani, M. L. Caramori, and T. Zelmanovitz Diabetic Nephropathy: Diagnosis, Prevention, and Treatment Diabetes Care, January 1, 2005; 28(1): 164 - 176. [Abstract] [Full Text] [PDF]

				J. Ran, T. Hirano, and M. Adachi Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats Am J Physiol Endocrinol Metab, November 1, 2004; 287(5): E955 - E961. [Abstract] [Full Text] [PDF]

				J. D Coyle, S. F Gardner, and C M. White The Renal Protective Effects of Angiotensin II Receptor Blockers in Type 2 Diabetes Mellitus Ann. Pharmacother., October 1, 2004; 38(10): 1731 - 1738. [Abstract] [Full Text] [PDF]

				J. Ran, T. Hirano, and M. Adachi Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats Am J Physiol Endocrinol Metab, August 1, 2004; 287(2): E227 - E232. [Abstract] [Full Text] [PDF]